Sigyn Therapeutics has appointed Michael Ryan to its Board of Directors, bringing substantial experience in early-stage technology and life science investments. Ryan, a Founding Director of Irrus Investments, Ltd., represents a significant addition to the company's strategic leadership.
With an extensive background in medical technology, Ryan has demonstrated a track record of supporting innovative healthcare ventures. As the largest angel investment syndicate in Ireland, Irrus Investments has committed over $50 million to 40 early-stage companies across multiple countries, highlighting Ryan's expansive network and investment acumen.
Prior to joining Sigyn's board, Ryan served as Chief Executive Officer of Sedana Medical, guiding the company to a successful stock exchange launch in Stockholm. His professional credentials include a Bachelor's in Mechanical Engineering and a Master's in Industrial Engineering from University College Dublin.
Sigyn Therapeutics is developing blood purification technologies targeting critical medical challenges, including life-threatening infections and cancer therapy enhancement. The company's lead product, Sigyn Therapy, has demonstrated potential in reducing viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma.
Ryan's appointment comes at a strategic moment for Sigyn, as the company advances its clinical protocols and explores innovative treatments for conditions like endotoxemia, sepsis, and end-stage renal disease. His expertise could prove instrumental in navigating the complex landscape of medical technology development and commercialization.
The addition of Ryan to the board underscores Sigyn Therapeutics' commitment to bringing cutting-edge medical technologies to market. His investment experience and strategic insights are expected to support the company's mission of developing life-saving therapeutic approaches.
